Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.68 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1260 | 1.00 | TRPA1 (0.68) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| SCHEMBL60429 | 1.00 | TRPA1 (0.68) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| SCHEMBL8976575 | 0.97 | TRPA1 (0.65) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| SCHEMBL8939138 | 0.97 | TRPA1 (0.65) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| Hydrochloric Acid SCHEMBL28757862 | 0.97 | TRPA1 (0.65) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| Methane SCHEMBL27517092 | 0.97 | TRPA1 (0.65) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28122152 | 0.97 | TRPA1 (0.65) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| Methylamine SCHEMBL10944526 | 0.93 | TRPA1 (0.61) | TRPA1TAAR1AOC3RIPK1KDM4E | |
| Acetic Acid SCHEMBL6330530 | 0.91 | TRPA1 (0.59) | TRPA1TAAR1AOC3RIPK1 | |
| SCHEMBL28632394 | 0.91 | TRPA1 (0.59) | TRPA1TAAR1AOC3RIPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | claimed |
| CN-119403908-A | Method for enhancing psychological performance and composition for use in the method | 弗门尼舍有限公司 | 2025-02-07 | — | — | CN | claimed |
| WO-2023247604-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | FIRMENICH SA (CH) | 2023-12-28 | — | — | WO | claimed |
| CN-106119113-B | Organisms for the production of 1, 3-butanediol | 基因组股份公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | AGAIN BIO APS (DK) | 2025-11-27 | — | — | US | disclosed |
| EP-4608839-A1 | SPIROCYCLE CONTAINING BICYCLIC HETEROARYL COMPOUNDS | Protego Biopharma, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12312627-B2 | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds | GENOMATICA, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | disclosed |
| CN-119403908-A | Method for enhancing psychological performance and composition for use in the method | 弗门尼舍有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-4414451-A2 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4 HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | Genomatica, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-1066236-A4 | PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE | RES FOUNDATION OF (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1066236-A1 | PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE | The Research Foundation of State University of New York (US) | 2001-01-10 | — | — | EP | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| US-6002037-A | INTERMEDIATES OF CHIRAL ORGANIC COMPOUNDS, E.G., ISOALKYL ALCOHOLS, IN HIGHLY ENANTIOMERIC EXCESS FOR PREPARING VITAMINS, DRUGS AND BIOMOLECULES; METALLOCENE CATALYSTS | PURDUE RESEARCH FOUNDATION (US) | 1999-12-14 | — | — | US | disclosed |
| WO-1999050214-A1 | PROCESS FOR HYDROCARBONYLATIONS IN SUPERCRITICAL CARBON DIOXIDE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-10-07 | — | — | WO | disclosed |
| US-5962744-A | USING CATALYST COMPLEX CONTAINING TRANSITION METAL AND PHOSPHITE LIGAND | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-10-05 | — | — | US | disclosed |
| CN-1148381-A | Benzene-fused heterocyclic derivative and use thereof | TORAY INDUSTRIES (JP) | 1997-04-23 | — | — | CN | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | HSD17B10, HSD17B12, HADHB | TRPA1 3196/4885TAAR1 2366/4885AOC3 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.